# A First-in-human Study to Evaluate Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Preliminary Anti-tumour Activity of TAX2 in Patients With Relapsed/Refractory Advanced/Metastatic Solid Tumours

> **NCT07688148** · PHASE1,PHASE2 · NOT_YET_RECRUITING · sponsor: **Apmonia Therapeutics** · enrollment: 48 (estimated)

## Conditions studied

- Solid Tumor Cancers

## Interventions

- **DRUG:** TAX2

## Key facts

- **NCT ID:** NCT07688148
- **Lead sponsor:** Apmonia Therapeutics
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-10
- **Primary completion:** 2029-02
- **Final completion:** 2030-08
- **Target enrollment:** 48 (ESTIMATED)
- **Last updated:** 2026-07-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07688148

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07688148, "A First-in-human Study to Evaluate Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Preliminary Anti-tumour Activity of TAX2 in Patients With Relapsed/Refractory Advanced/Metastatic Solid Tumours". Retrieved via MORVS 2026-10-20 from https://api.morvs.ai/clinical/NCT07688148. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*